Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G ...

"Eli Lilly seeks more GPCR weight loss drugs in $1.3bn research deal" was originally created and published by Pharmaceutical ...

Superluminal Medicines, a drug discovery company integrating AI/ML, protein dynamics, and structural biology announced a collaboration with Eli ...

On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion.

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal focused on treating hearing loss. The centerpiece of the agreement is ...

Eli Lilly (NYSE: LLY) reported its Q1 2025 earnings a few weeks ago, and it was said to have achieved an accelerated growth in revenue of 45% to $12.73 billion.